PharmaShots | Incisive News in 3 Shots

Subscribe Now

Muscle Invasive Urothelial Carcinoma

BMS Reports the US FDA's Acceptance of Opdivo's sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma

BMS Reports the US FDA's Acceptance of Opdivo's sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma

April 30, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us